Fan Pinchao, Zhu Chengjun, Guan Xiaoxiang
Department of Oncology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China.
The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China.
J Immunother Cancer. 2025 Apr 30;13(4):e011899. doi: 10.1136/jitc-2025-011899.
Over the past decade, combining immune checkpoint blockade with chemotherapy has reshaped the paradigm of triple-negative breast cancer (TNBC), but the cellular dynamics in the tumor immune microenvironment (TIME) that orchestrate clinical response remain elusive. In a recent issue of , Zhang integrated murine and human single-cell sequencing data, and unveiled that tumor-infiltrating mast cells (TIMCs) could exert distinct antitumor effects by enriching and fueling various immune cell clusters, suggesting the pivotal tuning role of TIMCs in the TIME of TNBC, as well as paving promising avenues for future TIMC-targeting therapies in synergy with chemoimmunotherapy against TNBC.
在过去十年中，免疫检查点阻断与化疗相结合重塑了三阴性乳腺癌（TNBC）的治疗模式，但协调临床反应的肿瘤免疫微环境（TIME）中的细胞动力学仍不清楚。在最近一期的《》杂志中，张（音译）整合了小鼠和人类单细胞测序数据，揭示肿瘤浸润肥大细胞（TIMC）可通过富集和促进各种免疫细胞簇发挥不同的抗肿瘤作用，这表明TIMC在TNBC的TIME中具有关键的调节作用，也为未来与TNBC化学免疫疗法协同作用的TIMC靶向治疗开辟了有前景的途径。
